


PHARMACEUTICAL 2019



CAMBREX CORP Rank 37 of 371





PHARMACEUTICAL 2019



CAMBREX CORP Rank 37 of 371

The relative strengths and weaknesses of CAMBREX CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CAMBREX CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 307% points. The greatest weakness of CAMBREX CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 133% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 449% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	410,092
Cost of Goods Sold	335,405
Intangible Assets	448,300
Liabilities, Current	104,412
Liabilities, Non-Current	65,795
Other Assets	4,508
Other Compr. Net Income	-17,909
Other Expenses	27,735
Other Liabilities	399,494
Other Net Income	7,518
Property and Equipment	360,528
Research and Development	15,547
Revenues	532,093
Selling, General and Administrative Expense	68,506

Output Variable	Value in 1000 USD
Assets	1,223,428
Liabilities	569,701
Expenses	447,193
Stockholders Equity	653,727
Net Income	92,418
Comprehensive Net Income	83,464
Economic Capital Ratio	118%